載入中
NASDAQHealthcareBiotechnology
最新資料
US$1.83
+US$0.02 · +1.10%
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
前收盤價
US$1.83
+US$0.02 · +1.10%
盤中時間採用ET。市場資料可能有所延遲。
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
日內區間
目前US$1.83
52週區間
目前US$1.83
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
43
合理估值
情緒
56
多空交錯
風險
89
極高風險
動能
20
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
日內區間
目前US$1.83
52週區間
目前US$1.83
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$11.83
上漲空間 546.45%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI326.81萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM223.66萬0.00%787.4億 USD0.19%US$278.94+0.49%
Fidelity Enhanced Small Cap ETFFESM113.74萬0.02%64.1億 USD0.28%US$45.46+0.46%
Vanguard Extended Market ETFVXF107.36萬0.00%954億 USD0.05%US$235+0.80%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV97.91萬0.00%268.09億 USD0.33%US$37.95-0.39%
iShares Biotechnology ETFIBB68.94萬0.01%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO57.18萬0.00%180億 USD0.06%US$112.66+0.50%
EA Bridgeway Omni Small-Cap Value ETFBSVO51萬0.02%23.91億 USD0.45%US$28.37-0.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMFidelity Enhanced Small Cap ETFFESMVanguard Extended Market ETFVXFU.S. Small Cap Value Portfolio ETF Class SharesDFSViShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOEA Bridgeway Omni Small-Cap Value ETFBSVOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
